Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial

Diabetes Research and Clinical Practice

Volumn 109, Issue 3, 2015, Pages e32-e35

  Rajagopalan, Sujit ^a   Dutta, Pinaki ^a   Hota, Debasish ^b   Bhansali, Anil ^a   Srinivasan, Anand ^a   Chakrabarti, Amitava ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Insulin resistance; Low dose; Pioglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LIPID;

ADD ON THERAPY; ADULT; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; INSULIN RESISTANCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SOUTHEAST ASIAN; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT GAIN; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; SOUTHEAST ASIA;

ADULT; ASIA, SOUTHEASTERN; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 84940786764     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.05.030     Document Type: Article

References (6)

1. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419. [Epub 1985/07/01].
2. Aronoff S., Rosenblatt S., Braithwaite S., Egan J.W., Mathisen A.L., Schneider R.L. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with Type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 study group. Diabetes Care 2000, 23(11):1605-1611. [Epub 2000/11/25].
3. Liew C.F., Seah E.S., Yeo K.P., Lee K.O., Wise S.D. Lean, nondiabetic Asian Indians have decreased insulin sensitivity and insulin clearance, and raised leptin compared to Caucasians and Chinese subjects. Int J Obes Relat Metab Disord: J Int Assoc Study Obes 2003, 27(7):784-789. [Epub 2003/06/25].
4. Balaji V. Efficacy and safety of pioglitazone in Type 2 diabetes in the Indian patients: results of an observational study. Indian J Endocrinol Metab 2013, 17(4):709-715. [Epub 2013/08/21].
5. Piccinni C., Motola D., Marchesini G., Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011, 34(6):1369-1371. [Epub 2011/04/26].
6. Mohan V., Bedi S., Unnikrishnan R., Sahay B.K., Joshpi S., Misra A. Pioglitazone-where do we stand in India?. J Assoc Physicians India 2012, 60:68-70. [Epub 2012/06/22].